Is telomerase a viable target in cancer?

被引：106
作者：
Buseman, C. M. [1 ]
Wright, W. E. [1 ]
Shay, J. W. [1 ]
机构：
[1] Univ Texas SW Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA
来源：
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS | 2012年 / 730卷 / 1-2期
关键词：
Senescence; Telomeres; Virotherapy; Immunotherapy; CYTOTOXIC T-LYMPHOCYTES; SUICIDE GENE-THERAPY; ARMED ONCOLYTIC ADENOVIRUS; TUMOR-ASSOCIATED ANTIGEN; REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT; TEMPLATE ANTAGONIST; PANCREATIC-CANCER; IN-VITRO; POTENTIAL ANTICANCER;
D O I：
10.1016/j.mrfmmm.2011.07.006
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
The ideal cancer treatment would specifically target cancer cells yet have minimal or no adverse effects on normal somatic cells. Telomerase, the ribonucleoprotein reverse transcriptase that maintains the ends of human chromosome, is an attractive cancer therapeutic target for exactly this reason [1]. Telomerase is expressed in more than 85% of cancer cells, making it a nearly universal cancer marker, while the majority of normal somatic cells are telomerase negative. Telomerase activity confers limitless replicative potential to cancer cells, a hallmark of cancer which must be attained for the continued growth that characterizes almost all advanced neoplasms [2]. In this review we will summarize the role of telomeres and telomerase in cancer cells, and how properties of telomerase are being exploited to create targeted cancer therapies including telomerase inhibitors, telomerase-targeted immunotherapies and telomerase-driven virotherapies. A frank and balanced assessment of the current state of telomerase inhibitors with caveats and potential limitations will be included. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码：90 / 97
页数：8
相关论文
共 139 条
[81]   Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. [J].
Nair, SK ;
Heiser, A ;
Boczkowski, D ;
Majumdar, A ;
Naoe, M ;
Lebkowski, JS ;
Vieweg, J ;
Gilboa, E .
NATURE MEDICINE, 2000, 6 (09) :1011-1017
[82]   Use of telomelysin (OBP-301) in mouse xenografts of human head and neck cancer [J].
Nakajima, Oumi ;
Ichimaru, Daiju ;
Urata, Yasuo ;
Fujiwara, Toshiyoshi ;
Horibe, Tomohisa ;
Kohno, Masayuki ;
Kawakami, Koji .
ONCOLOGY REPORTS, 2009, 22 (05) :1039-1043
[83]   Telomerase catalytic subunit homologs from fission yeast and human [J].
Nakamura, TM ;
Morin, GB ;
Chapman, KB ;
Weinrich, SL ;
Andrews, WH ;
Lingner, J ;
Harley, CB ;
Cech, TR .
SCIENCE, 1997, 277 (5328) :955-959
[84]  
Nava-Parada P, 2007, CURR OPIN MOL THER, V9, P490
[85]   A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors [J].
Nemunaitis, John ;
Tong, Alex W. ;
Nemunaitis, Michael ;
Senzer, Neil ;
Phadke, Anagha P. ;
Bedell, Cynthia ;
Adams, Ned ;
Zhang, Yu-An ;
Maples, Phillip B. ;
Chen, Salina ;
Pappen, Beena ;
Burke, James ;
Ichimaru, Daiju ;
Urata, Yasuo ;
Fujiwara, Toshiyoshi .
MOLECULAR THERAPY, 2010, 18 (02) :429-434
[86]   Inhibition of human telomerase activity by peptide nucleic acids [J].
Norton, JC ;
Piatyszek, MA ;
Wright, WE ;
Shay, JW ;
Corey, DR .
NATURE BIOTECHNOLOGY, 1996, 14 (05) :615-619
[87]  
Ouellette M.M., 2007, ENCY LIFE SCI
[88]   Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts [J].
Ozawa, T ;
Gryaznov, SM ;
Hu, LJ ;
Pongracz, K ;
Santos, RA ;
Bollen, AW ;
Lamborn, KR ;
Deen, DF .
NEURO-ONCOLOGY, 2004, 6 (03) :218-226
[89]   How Shelterin Protects Mammalian Telomeres [J].
Palm, Wilhelm ;
de Lange, Titia .
ANNUAL REVIEW OF GENETICS, 2008, 42 :301-334
[90]   Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954 [J].
Plumb, JA ;
Bilsland, A ;
Kakani, R ;
Zhao, JQ ;
Glasspool, RM ;
Knox, RJ ;
Evans, TRJ ;
Keith, WN .
ONCOGENE, 2001, 20 (53) :7797-7803
45678910111213